Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: nitrogen who wrote (112711)	2/20/2003 9:53:53 AM
From: Jim Bishop	Read Replies (2) \| Respond to of 150070

DBOT Demegen Receives Patent for Method of Treating HIV Thursday February 20, 9:46 am ET PITTSBURGH, Feb. 20 /PRNewswire-FirstCall/ -- Demegen, Inc. (OTC Bulletin Board: DBOT - News), a biotechnology company specializing in the development of peptides for the treatment of infectious diseases, announced today it had received United States patent 6,514,692 for a method of treating immunodeficiency virus infection. The primary claim of the patent is a method of reducing cell-to-cell transmission of an immunodeficiency virus (including HIV and FIV) comprising administering to an animal infected with an immunodeficiency virus an amount of a lytic peptide that is lethal neither to the virus nor to virus-infected cells, but that renders viral particles produced by the infected animal non- infectious. Demegen is seeking a license partner to assist with the development of a drug to treat HIV. The peptides described in this patent are protected by composition of matters claims allowed in previous Demegen patents. Demegen develops novel and natural peptides for the treatment of bacterial and fungal infections. Products to be developed include treatments for cystic fibrosis infections, for which there is an Orphan Drug designation, oral candidiasis, dermatological diseases, and sexually transmitted infections. Demegen's website is demegen.com. This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (as amended, the "Act"). In particular, when used herein, the words "plan," "estimates," "should," "confident that," "believe," "expect," or "intend to," and similar expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward- looking statements. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the Company's products and technologies, possible delays or failures to develop and/or commercialize any technology, possible risks related to adverse clinical results, impact of alternative technology advances, inherent risks in early stage development of such technology, competitive factors, the ability to successfully complete additional financings, continuing to function as a viable going-concern, and other risks described in the Company's reports and filings with the Securities and Exchange Commission. Contacts: Demegen, Inc., Richard Ekstrom, President 412-241-2150, E-mail: info@demegen.com; www.demegen.com -------------------------------------------------------------------------------- Source: Demegen, Inc.